More than a decade ago, nanotechnology became an integral part of the overall scientific research world. Governments started funding programs specifically aimed at nanotechnology, research universities opened their facilities and coursework to the new discipline, and journals focusing on nano research became commonplace.And now, many researchers believe, its nanomedicines turn to do the same. Nanomedicinewhich has emerged as nanotechnologys most important sub-disciplineis the application of nanotechnology to the prevention and treatment of disease in the human body. It is already having an impact clinically among some of the deadliest diseases in the world.
Nanomedicine is far from the stuff of science fiction. The possibilities for nanomedicine to help us diagnose, treat and image diseases are endless. Imagine a smart nanomedicine that is able to bind to tumor cells and enhance imaging and diagnosis, at the same time as being able to deliver a gene therapy or chemotherapy agent. With the technologies available to us and our multidisciplinary teams, this will be possible in my lifetime, said Phoebe Phillips, head of the pancreatic cancer translational research group at the University of New South Wales in Sydney.
Phillips and her team have created a nanoparticle that dramatically increases its effectiveness as an anti-cancer drug for patients with pancreatic cancers, which is one of the fastest killing cancers from time of initial detection, often leaving patients with no suitable treatment options and only weeks to live.
While nanomedicine canand likely willplay a role in diagnostics, regenerative medicine, prosthetics and more, the effect the sub-discipline is currently having on the treatment of autoimmune diseases and cancers is significant.
Nanomedicine for HIVThirty years ago, a diagnosis of HIV/AIDS was essentially a guarantee of a painful, protracted death. It wasnt until 1996 that researchers discovered antiretroviral drugs, and the potent combination therapy that leads to successful management of HIV/AIDS in most cases. However, not much has changed since that discovery. Those suffering from the autoimmune disease still require daily oral dosing of three to four pills, and chronic oral dosing has significant complications that can arise from the high pill burden experienced by patients, leading to non-adherence to therapies for a variety of reasons.
Ive been working in HIV for over 20 years, Andrew Owen, professor of molecular and clinical pharmacology at the University of Liverpool (UK) told Laboratory Equipment. I was trying to understand the variability in drug exposure that occurs between different individuals and the genetic basis for that. We were finding a lot of interesting things, but they werent clinically implementable. They gave us a good understanding of why drug exposure was variable, but it didnt actually help the patients in any way.
In an attempt to solve the problem rather than just characterize it, Owen turned to nanomedicine in 2009, eventually becoming part of the first team to conduct human trials of orally dosed nanomedicines for HIV. Since then, Owen and his interdisciplinary team at the Liverpool Nanomedicine Partnership have secured more than 20 million of research funding for a multitude of nanomedicine-based approaches to HIV, such low-dose oral delivery, long-acting injectable medications and targeted delivery of antiretrovirals.
Some of Owens most important research to date tackles two of the pharmaceutical industrys biggest challenges: oral delivery of potent drugs and supply and demand.
One of the major problems that has plagued drug discovery and drug development over the last 30 years has been compatibility with oral drug delivery, Owen explained. The pharmaceutical industry has wrestled with that because they can develop very potent molecules across diseases, but actually delivering those molecules orally is very challenging. As you try to design into the molecule oral bioavailabilty, you usually get further away from the potency you want.
The Liverpool team solved this problem with the creation of Solid Drug Nanoparticles. The technology consists of combining a normal drug, in its solid form, with particles on that drug that are measurable within the nanometer scale. There are other things packed into the formulation as well, such as FDA-approved stabilizers that are proven to help disperse the drug. Owen says it is all about increasing the surface area covered by the drug.
If you imagine you take a granulated form of the drug, youre going to get big chunks of drugs in the intestinal tract when dissolution happens. But if you have nanometer-sized particles within the GI tract, then you are going to get a complete coating of the inside of the intestine after you take the drug, Owen explained. What that does is it massively increases the surface area covered by the drug, which saturates all sorts of drug influx processes within the GI tract.
Since 80 percent of a humans immune system is concentrated in the gut, the Solid Drug Nanoparticles are the perfect mechanism. The immune cells in the gut instinctually move toward the particles, creating a pathway for the drugs to cross the intestines, move through the lymphatic system, and finally into the systematic circulation.
In February, Owen presented the results of two trials at the Conference on Retroviruses and Opportunistic Infections (CROI) that confirmed his Solid Drug Nanoparticles can be effective at a 50 percent dose reduction. Specifically, Owen and his team applied the nanomedicine-based approach to the formulation of two drugs: efvirenz (EFV) and lopinavir (LPV). EFV is the current WHO-recommended regimen, with 70 percent of adult HIV patients in low- and middle-income countries taking the medication. At 50 percent of the dose, the patients in the trial were able to maintain plasma concentrations of the conventional dose.
Globally, the supply of drugs needed to treat every patient with HIV is outstripping manufacturing capabilitymeaning we, as a human species, cannot physically make enough HIV medication to treat everyone with the disease. A 50 percent reduction in dose means twice as many patients served with the existing drug supply.Owen and his team are working with multiple global partners to move the technology forward. For the drugs already formulated, the Medicines Patent Pool and Clinical Health Access are helping to scale up and take them to market. Meanwhile, USAIDs Project OPTIMIZE is applying the nanoparticle technology to the newest HIV drugs for use in low- and middle-income countries.
For their latest collaboration with Johns Hopkins University, the Liverpool team was just awarded $3 million to examine the use of implantable technologies that can deliver drugs for weeks, or even months.
The current oral drug regimens for HIV comprises three drugs in combinationone is the major driver for efficacy, and the other two are nucleoside reverse transcriptase inhibitors that prevent resistance to the main drug. However, current injectable formulations are only available with the main drugnone include the nucleoside reverse transcriptase inhibitors.
So, our project aims to develop the first long-acting injectable nucleoside reverse transcriptase inhibitors so that we can use them to have a fully long-acting regimen that matches the current clinical paradigm for therapy, Owen said.
The Liverpool/Hopkins team has also thought about applying their long-acting injectable technology to other chronic diseases, such as malaria and tuberculosis, as well as some cardiovascular applications.
Nanomedicine for diabetesWhen the nanoparticles he was working with as an imaging tool didnt produce the desired results, Pere Santamaria grew frustratedbut he didnt give up. Instead, the doctor and professor at the University of Calgary (Canada) changed his assumptions and pursued his experimentuntil the data came pouring in that confirmed it wasnt a failed experiment at all. Rather, it was a discovery.
The discovery of Navacims was a bit serendipitous, Santamaria told Laboratory Equipment. Thankfully I am a little OCD and I didnt let the failed experiment go.Navacims are an entirely new class of nanomedicine drugs that harness the ability to stop disease without impairing normal immunity. Santamaria has been studying Navacims for the past 17 years, ever since unintentionally developing them. He even started a spin-off company, Parvus Therapeutics, Inc., to help bring the drugs to market.
In autoimmune diseases, white blood cells, which are normally responsible for warding off foreign invaders and disease, turn on the body, attacking the good cells and causing their destruction. Each specific autoimmune disease results from an attack against thousands of individual protein fragments in the targeted organ, such as the insulin-producing pancreatic cells in the case of type 1 diabetes.
But Santamarias studies show that nanoparticles decorated with protein targets acting as bait for disease-causing white blood cells can actually be used to reprogram the cells to rightfully suppress the disease they once intended to cause.
Once the immune system recognizes the presence of a Navacim, a white blood cell is reprogrammed by epigenetic changes into a lymphocyte that no longer wants to cause tissue damage, but rather work to suppress disease. According to Santamaria, the reprogramming step is immediately followed by an expansion of that population of lymphocytesone now-good white blood cell dividing into a million.
Basically they turn the tables on the immune system, and then there is a very sophisticated series of downstream cellular events that arise from that reprogramming event that involves the recruitment of other lymphocytes and other cell types that completely suppress the inflammation in the organ that is being infected, Santamaria explained. This happens extremely efficiently and comprehensively. This is an approach that can efficiently, selectively and specifically blend a complex response without impairing basic immunity.
In addition, the design of Navacims is modular, meaning the nanomedicine can be applied to severalif not allautoimmune diseases, including multiple sclerosis and rheumatoid arthritis. Navacims can be altered to target different diseases by simply changing a small portion of the bait molecules on the nanoparticles. Santamarias studies have shown this to work in about seven autoimmune diseases thus far.
In April, Santamarias company Parvus entered into a license and collaboration agreement with Novartis for Navacims. Under the terms of the agreement, Novartis receives exclusive worldwide rights to use Parvus Navacim technology to develop and commercialize products for the treatment of type 1 diabetes, and will be responsible for clinical-stage development and commercialization. Parvus will still be responsible for conducting ongoing preclinical work in the diabetes area, with some research funding from Novartis.
Weve had such a long time to prove ourselves, that this is not a flash in the pan, that this is something serious and robust, Santamaria said. We know so much about the mechanisms of our actions, and so much granularity. I think there are no other drugs that have reached the clinic with this level of understanding. That was painful in the beginning for us, but in the end its going to be good.
Read the original here:
The Promise of Nanomedicine - Laboratory Equipment
- Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes - December 18th, 2022
- www.the-scientist.com - December 18th, 2022
- Applications of Nanotechnology - National Nanotechnology Initiative - December 18th, 2022
- Nanotechnology Timeline | National Nanotechnology Initiative - October 29th, 2022
- Nano based drug delivery systems: recent developments and future ... - October 21st, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 16th, 2022
- 'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom - September 16th, 2022
- International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld - September 16th, 2022
- Reebok Nano X2 Adventure Review: A Wild Way to Log Your Workouts - Gear Patrol - August 30th, 2022
- PhD within Particle Engineering job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 306487 - Times Higher Education - August 30th, 2022
- Nanoparticles' Role in Eliminating Cancer Cells - MedTech Outlook - August 22nd, 2022
- The first female astronaut from a North African nation will be a Tunisian military aviator - Atalayar - August 22nd, 2022
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition | npj Digital Medicine - Nature.com - August 22nd, 2022
- Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol - August 14th, 2022
- How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle - August 14th, 2022
- Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and... - July 27th, 2022
- Nanorobots Market to close to USD 19576.43 million with CAGR of 12.23% during the forecast period to 2029 - Digital Journal - July 27th, 2022
- Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development... - July 27th, 2022
- Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire - July 19th, 2022
- Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo... - July 19th, 2022
- Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal - July 11th, 2022
- Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM - July 11th, 2022
- Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine - July 11th, 2022
- Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading... - July 11th, 2022
- Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women - July 11th, 2022
- Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - July 11th, 2022
- $2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News - June 22nd, 2022
- New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The... - June 22nd, 2022
- Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women... - June 22nd, 2022
- An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com - June 13th, 2022
- Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld - June 4th, 2022
- New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace - June 4th, 2022
- Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint... - May 15th, 2022
- Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian - May 2nd, 2022
- Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt... - May 2nd, 2022
- Cancer and Nanotechnology - National Cancer Institute - April 19th, 2022
- Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal - April 19th, 2022
- ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil - April 19th, 2022
- Nano Products Online Store | Nanoproducts, Nanoparticles ... - April 6th, 2022
- The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients - Business Wire - March 25th, 2022
- Space the next frontier for cancer treatment? - Australian Jewish News - March 25th, 2022
- ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of... - January 20th, 2022
- Surface Modification and Size Contribute to Nanoplastic Toxicity - AZoNano - January 20th, 2022
- Frontiers | Nanomedicine: Principles, Properties, and ... - January 5th, 2022
- Nanotechnology In Medicine: Huge Potential, But What Are ... - January 5th, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 5th, 2022
- 2009 show based on conspiracy theories is shared as proof of WHO working on COVID-19 vaccines to create permanent sterility - Factly - January 5th, 2022
- How to Improve Infectious Diseases with Nanotechnology - CIO Applications - January 5th, 2022
- Biodistribution of sphingolipid nanoemulsions with 68Ga | IJN - Dove Medical Press - August 31st, 2021
- Matrix Meats Adds to Team as Interest in Cultivated Meat Grows - PRNewswire - July 21st, 2021
- Nanomedicine in Central Nervous System Injury and Repair Market Report- Trends Key Programs Analysis and Competitive Landscape Analysis The Manomet... - June 23rd, 2021
- Nanomedicine is transforming healthcare innovation - Korea IT Times - June 6th, 2021
- The Future of Cancer Treatment Using Nanotechnology - AZoNano - June 6th, 2021
- Thomas Jefferson Awards Highlight Research and Service to the University - UVA Today - June 6th, 2021
- Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to... - October 31st, 2020
- Nanox Signs With Ambra Health to Enable Image Access and Transfer with US Hospitals and Medical imaging Providers - BioSpace - October 31st, 2020
- Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 29th, 2020
- What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network - September 23rd, 2020
- Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas - August 29th, 2020
- Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving... - August 12th, 2020
- Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace - June 17th, 2020
- Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire - June 17th, 2020
- Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type... - June 15th, 2020
- Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK - June 15th, 2020
- Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -... - June 15th, 2020
- Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY - June 10th, 2020
- Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca - May 24th, 2020
- Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press - May 10th, 2020
- The future of medicine - Switzer Financial News - May 10th, 2020
- All your questions about how to wear a face mask -- answered - Action News Now - April 26th, 2020
- Edited Transcript of NANO earnings conference call or presentation 6-Feb-20 9:30pm GMT - Yahoo Finance - February 11th, 2020
- Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance - February 11th, 2020
- Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace - February 11th, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - February 6th, 2020
- The Future Of Nano Medicine - February 6th, 2020
- VVUS Stock Jumps 70% on FDA Nod for New Formulation of Pancreaze - MicroSmallCap - February 6th, 2020
- Is the Lieber Arrest Linked to Military Brain Research and China? - Bryen's Blog - February 6th, 2020
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press - January 10th, 2020
- Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News - January 10th, 2020
- Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News - January 10th, 2020